Charles Giamberardino

Mr. Charles Giamberardino

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2022 in mBio
Verified
Journal Article
Open access
CGCharles Giamberardino
Charles Giamberardino
WSWiley A. Schell
Wiley A. Schell
JTJennifer L. Tenor
Jennifer L. Tenor
DTDena L. Toffaletti
Dena L. Toffaletti
JPJulia R. Palmucci
Julia R. Palmucci
Karen ShawKaren Shaw
Karen Shaw
Cryptococcal meningitis (CM) is a fungal disease with significant global morbidity and mortality. The gepix Gwt1 inhibitors are a new class of antifungal drugs.

16 August 2023 in Infection and Immunity
Verified
Journal Article
Closed access
JMJulia A. Messina
Julia A. Messina
CGCharles Giamberardino
Charles Giamberardino
JTJennifer L. Tenor
Jennifer L. Tenor
DTDena L. Toffaletti
Dena L. Toffaletti
WSWiley A. Schell
Wiley A. Schell
JPJohn R. Perfect
John R. Perfect
Patients receiving the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib have an increased likelihood of fungal infections. The objectives of this study were to determine if Cryptococcus neoformans infection severity was isolate dependent with BTK inhibition and whether blocking BTK impacted infection severity in a mouse model.

8 May 2024 in mBio
Verified
Journal Article
Open access
JPJulia R. Palmucci
Julia R. Palmucci
BSBlake E. Sells
Blake E. Sells
CGCharles Giamberardino
Charles Giamberardino
DTDena L. Toffaletti
Dena L. Toffaletti
BDBaodi Dai
Baodi Dai
John PerfectJohn Perfect
John Perfect
Invasive fungal infections are a significant public health concern, with mortality rates ranging from 20% to 85% despite current treatments. Therefore, we examined whether a ketogenic diet could serve as a successful treatment intervention in murine models of Cryptococcus neoformans and Candida albicans infection in combination with fluconazole—a low-cost, readily available antifungal therapy. The ketogenic diet is a high-fat, low-carbohydrate diet that promotes fatty acid oxidation as an alternative to glycolysis through the production of ketone bodies. In this series of experiments, mice fed a ketogenic diet prior to infection with C. neoformans and treated with fluconazole had a significant decrease in fungal burden in both the brain (mean 2.66 ± 0.289 log 10 reduction) and lung (mean 1.72 ± 0.399 log 10 reduction) compared to fluconazole treatment on a conventional diet. During C. albicans infection, kidney fungal burden of mice in the keto-fluconazole combination group was significantly decreased compared to fluconazole alone (2.37 ± 0.770 log 10 -reduction). Along with higher concentrations of fluconazole in the plasma and brain tissue, fluconazole efficacy was maximized at a significantly lower concentration on a keto diet compared to a conventional diet, indicating a dramatic effect on fluconazole pharmacodynamics. Our findings indicate that a ketogenic diet potentiates the effect of fluconazole at multiple body sites during both C. neoformans and C. albicans infection and could have practical and promising treatment implications. IMPORTANCE: Invasive fungal infections cause over 2.5 million deaths per year around the world. Treatments for fungal infections are limited, and there is a significant need to develop strategies to enhance antifungal efficacy, combat antifungal resistance, and mitigate treatment side effects. We determined that a high-fat, low-carbohydrate ketogenic diet significantly potentiated the therapeutic effect of fluconazole, which resulted in a substantial decrease in tissue fungal burden of both C. neoformans and C. albicans in experimental animal models. We believe this work is the first of its kind to demonstrate that diet can dramatically influence the treatment of fungal infections. These results highlight a novel strategy of antifungal drug enhancement and emphasize the need for future investigation into dietary effects on antifungal drug activity.

26 December 2022 in Cureus
Verified
Journal Article
Open access
VVVishal Venkatraman
Vishal Venkatraman
AFAnthony J. Filiano
Anthony J. Filiano
LXLi Xu
Li Xu
LCLeonard Collins
Leonard Collins
ELEmily Luo
Emily Luo
RBRichard S. Bedlack
Richard S. Bedlack
Introduction: Cerebrospinal fluid (CSF) has been implicated in amyotrophic lateral sclerosis (ALS) due to its ability to spread inflammatory proteins throughout the nervous system. We hypothesized that filtration of the CSF could remove pathogenic proteins and prevent them from altering motor phenotypes in a mouse model. Methods: We filtered the CSF from 11 ALS patients via 100 kilodaltons (kD) molecular weight cut-off filters. We used mass spectrometry-based discovery proteomics workflows to compare protein abundances before and after filtration. To test the effects of CSF filtration on motor function, we injected groups of mice with saline, filtered ALS-CSF, or unfiltered ALS-CSF (n=12 per group) and assessed motor function via pole descent and open field tests. Results: We identified proteins implicated in ALS pathogenesis and showed that these were removed in significant amounts in our workflow. Key filtered proteins included complement proteins, chitinases, serine protease inhibitors, and neuro-inflammatory proteins such as amyloid precursor protein, chromogranin A, and glial fibrillary acidic protein. Compared to the filtered ALS-CSF mice, unfiltered ALS-CSF mice took longer to descend a pole (10 days post-injection, 11.14 seconds vs 14.25 seconds, p = 0.02) and explored less on an open field (one day post-injection, 21.81 m vs 16.83 m, p = 0.0004). Conclusions: We demonstrated the ability to filter proteins from the CSF of ALS patients and identified potentially pathologic proteins that were reduced in quantity. Additionally, we demonstrated the ability of unfiltered ALS-CSF to induce motor deficits in mice on the pole descent and open field tests and showed that filtration could prevent this deficit. Given the lack of effective treatments for ALS, this could be a novel solution for patients suffering from this deadly and irreversible condition.

18 October 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
CGCharles Giamberardino
Charles Giamberardino
JTJennifer L. Tenor
Jennifer L. Tenor
DTDena L. Toffaletti
Dena L. Toffaletti
JPJulia R. Palmucci
Julia R. Palmucci
WSWiley Schell
Wiley Schell
John PerfectJohn Perfect
John Perfect
Cryptococcal meningoencephalitis (CM) is a devastating fungal disease with high morbidity and mortality. The current regimen that is standard-of-care involves a combination of three different drugs administered for up to one year. There is a critical need for new therapies due to both toxicity and inadequate fungicidal activity of the currently available antifungal drugs. ATI-2307 is a novel aryl amidine that disrupts the mitochondrial membrane potential and inhibits the respiratory chain complexes of fungi—it thus represents a new mechanism for direct antifungal action. Furthermore, ATI-2307 selectively targets fungal mitochondria via a fungal-specific transporter that is not present in mammalian cells. It has very potent in vitro anticryptococcal activity. In this study, the efficacy of ATI-2307 was tested in a rabbit model of CM. ATI-2307 demonstrated significant fungicidal activity at dosages between 1 and 2 mg/kg/d, and these results were superior to fluconazole and similar to amphotericin B treatment. When ATI-2307 was combined with fluconazole, the antifungal effect was greater than either therapy alone. While ATI-2307 has potent anticryptococcal activity in the subarachnoid space, its ability to reduce yeasts in the brain parenchyma was relatively less over the same study period. This new drug, with its unique mechanism of fungicidal action and ability to positively interact with an azole, has demonstrated sufficient anticryptococcal potential in this experimental setting to be further evaluated in clinical studies.

22 July 2025 in mBio
Verified
Journal Article
Open access
LPLukas M. du Plooy
Lukas M. du Plooy
CPCorinna Probst
Corinna Probst
MCMatthew E. Capobianco
Matthew E. Capobianco
CGCharles Giamberardino
Charles Giamberardino
CPClaudia A. Petrucco
Claudia A. Petrucco
JAJ. Andrew Alspaugh
J. Andrew Alspaugh
Pathogenic microorganisms use varied cellular processes to adapt to the particular stresses encountered in the infected host. These stresses include rapid alterations in ambient temperature, nutrient availability, and extracellular pH. Fungal pathogens, therefore, rely on the activation of stress response pathways such as the Pal/Rim pathway to adapt to the neutral pH encountered when infecting mammals. While this pathway is conserved among human pathogenic fungi, the proteins required for pH sensing appear to have diverged between different fungal phyla. The opportunistic fungal pathogen Cryptococcus neoformans , a basidiomycete, employs a pH-sensing protein in its Rim pathway that is distinct but functionally analogous to related proteins in well-studied ascomycete fungal systems. We recently characterized protein ubiquitination mediated through the Rsp5 ubiquitin ligase to be required for C. neoformans virulence and for microbial adaptations to host-relevant conditions, including growth at host pH levels. Here, we determined that C. neoformans Rsp5 is specifically required for Rim pathway activation. Using an unbiased screen for proteins that are ubiquitinated by Rsp5 in acidic and alkaline pH, we identified a new component of the C. neoformans Rim pathway that is targeted by Rsp5 for ubiquitination and shares protein features with the ascomycete Rim8/PalF proteins. Rsp5-mediated ubiquitination facilitates protein interactions with Vps23, a downstream trafficking component of the Pal/Rim pathway. Therefore, we define adaptation to ambient pH as one component of the broad cellular roles of Rsp5-mediated ubiquitination, as we explore how protein ubiquitination affects cryptococcal cell physiology, virulence, and microbial interactions with the host. IMPORTANCE: Exploring the molecular adaptations allowing fungi to grow in an ever-changing environment yields insight into how fungal pathogens adapt to the stresses present in the infected host. The fungal Rim/Pal pathway, activated during alkaline pH stress and during mammalian infection, is of particular interest because of the lack of a homologous pathway in other eukaryotes, providing an opportunity to identify novel targets for antimicrobial therapies with little damage to the host. There is evidence for convergent evolution in this pathway between ascomycetes and basidiomycetes, evident through the functionally converged, but sequence-dissimilar, sensing proteins found in these two fungal groups. Here, we identify the role of ubiquitination in the activation of the Cn Rim pathway. This ubiquitination event is mediated by the Rsp5 E3 Ub ligase and a basidiomycete-specific functional analog of the ascomycete PalF/Rim8 protein that is required for interaction with downstream components of this pathway.